Cirrhosis alcoholic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cirrhosis alcoholic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Carvedilol for Preventing Complications in Patients with Early-Stage Cirrhosis and High Blood Pressure in the Liver https://clinicaltrials.eu/trial/study-on-carvedilol-for-preventing-complications-in-patients-with-early-stage-cirrhosis-and-high-blood-pressure-in-the-liver/ Wed, 29 Apr 2026 15:03:32 +0000 https://clinicaltrials.eu/trial/study-on-carvedilol-for-preventing-complications-in-patients-with-early-stage-cirrhosis-and-high-blood-pressure-in-the-liver/ This clinical trial is focused on studying the effects of a medication called Carvedilol on patients with a liver condition known as cirrhosis. Cirrhosis is a disease where the liver becomes scarred and its function is impaired. The study specifically targets patients with a type of cirrhosis that is currently not causing symptoms, classified as Child-Pugh A5 to B8 cirrhosis, and who also have a condition called clinically significant portal hypertension. Portal hypertension is an increase in blood pressure within the portal vein, which carries blood from the digestive organs to the liver.

The purpose of the study is to evaluate whether taking a low dose of Carvedilol (up to 12.5 mg per day) can prevent the worsening of cirrhosis or liver-related death over a period of 36 months. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain any active ingredients. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored for any changes in their condition, including the occurrence of cirrhosis complications or liver-related death. The safety of Carvedilol will also be assessed by observing its effects on heart rate, blood pressure, and overall cardiac function. Additionally, researchers will look for any potential predictors of how patients respond to the treatment, such as changes in liver and spleen stiffness or variations in heart rate and blood pressure. The study aims to provide valuable insights into the management of cirrhosis and improve outcomes for patients with this condition.

]]> Study on Preventing Hepatic Encephalopathy with Rifaximin and Lactulose in Patients with Alcoholic Liver Cirrhosis Undergoing TIPS Placement https://clinicaltrials.eu/trial/study-on-preventing-hepatic-encephalopathy-with-rifaximin-and-lactulose-in-patients-with-alcoholic-liver-cirrhosis-undergoing-tips-placement/ Wed, 29 Apr 2026 14:58:19 +0000 https://clinicaltrials.eu/trial/study-on-preventing-hepatic-encephalopathy-with-rifaximin-and-lactulose-in-patients-with-alcoholic-liver-cirrhosis-undergoing-tips-placement/ This clinical trial is focused on studying the prevention of a condition called hepatic encephalopathy in patients with liver cirrhosis. Liver cirrhosis is a disease where the liver becomes severely scarred, often due to long-term damage such as from alcohol use. Hepatic encephalopathy is a complication that can occur in people with liver cirrhosis, leading to confusion and other mental changes. The trial involves patients who are undergoing a procedure known as a transjugular intrahepatic portosystemic shunt (TIPS), which is used to treat complications of liver cirrhosis.

The study will test the effectiveness of two medications, Rifaximin and Lactulose, in preventing hepatic encephalopathy after the TIPS procedure. Rifaximin is an antibiotic that works in the gut, and Lactulose is a type of sugar that helps reduce the amount of toxins in the blood. Some participants will receive these medications, while others will receive a placebo, which looks like the medication but does not contain any active ingredients. The purpose of the study is to see if taking Rifaximin and Lactulose can lower the chances of developing hepatic encephalopathy within the first three months after the TIPS procedure.

Participants in the study will be randomly assigned to receive either the medications or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medications and who is receiving the placebo. This helps ensure that the results are not biased. The trial will last for a period of up to 13 weeks, during which time participants will be monitored for any signs of hepatic encephalopathy and other health changes. The findings from this study could help improve the care and outcomes for patients with liver cirrhosis undergoing the TIPS procedure.

]]> Study on Dapagliflozin for Patients with Decompensated Liver Cirrhosis https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-decompensated-liver-cirrhosis/ Wed, 29 Apr 2026 14:27:54 +0000 https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-decompensated-liver-cirrhosis/ This clinical trial is focused on studying the effects of a medication called dapagliflozin in patients with a condition known as decompensated liver cirrhosis. Liver cirrhosis is a disease where the liver becomes severely scarred, and when it is decompensated, it means the liver is no longer able to function properly, leading to serious health issues. The purpose of this study is to evaluate the safety of using dapagliflozin compared to standard medical treatments for this condition.

Participants in the study will be randomly assigned to receive either dapagliflozin or a standard treatment, which may include a placebo. The study will monitor the participants over a period of several months to observe any side effects and to assess the overall health outcomes. The study will also track the occurrence of specific complications related to liver cirrhosis, such as bleeding from veins in the esophagus, confusion due to liver failure (known as hepatic encephalopathy), and fluid buildup in the abdomen (ascites).

Throughout the study, various health markers will be measured to understand the impact of dapagliflozin on liver function and overall health. These include changes in scores that assess liver disease severity, quality of life, and other health indicators. The study aims to provide valuable information on whether dapagliflozin can be a safe and effective treatment option for people with decompensated liver cirrhosis.

]]>